Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HG 302

Next Previous
Drug Profile

HG 302

Alternative Names: HG-302

Latest Information Update: 04 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HuidaGene Therapeutics
  • Class Gene therapies
  • Mechanism of Action Dystrophin expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Duchenne muscular dystrophy

Most Recent Events

  • 06 Nov 2024 Clinical trials in Duchenne muscular dystrophy (In children) in China (IV) (NCT06594094)
  • 05 Nov 2024 HG 302 receives Orphan Drug status for Duchenne muscular dystrophy in USA
  • 19 Sep 2024 HuidaGene Therapeutics plans a phase 0 MUSCLE trial for Duchenne muscular dystrophy (In children) in October 2024 (IV) (NCT06594094)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top